Clinical Guides
Breast Cancer
A clinically focused guide to recognising, diagnosing and coordinating breast cancer care in India, with triple assessment, subtype-directed multidisciplinary treatment, treatment-toxicity safety, referral pathways and explicit limits on applying non-Indian protocols.
MedNext Academy | 14 min read
Breast Cancer
A clinically focused guide to recognising, diagnosing and coordinating breast cancer care in India, with triple assessment, subtype-directed multidisciplinary treatment, treatment-toxicity safety, referral pathways and explicit limits on applying non-Indian protocols.
Summary
Breast cancer comprises malignant epithelial tumours arising most often from the terminal duct-lobular system. Invasive disease can extend through breast tissue, involve regional lymph nodes and metastasise; ductal carcinoma in situ remains confined by the basement membrane but still requires specialist management. A breast lump is a common presentation, yet malignancy may instead appear as focal thickening, architectural change, skin tethering, nipple inversion, pathological discharge, axillary lymphadenopathy or an inflammatory pattern. Pain does not reliably distinguish benign from malignant disease, and the absence of a family history is not reassuring enough to dismiss a new abnormality. Men can also develop breast cancer.
The diagnostic principle is concordant triple assessment: clinical assessment, appropriate breast imaging and tissue diagnosis. Imaging alone does not establish invasive histology or the biomarkers that guide therapy. Pathology should identify invasive versus in-situ disease, histological type and grade, and report oestrogen receptor, progesterone receptor and HER2 status using validated methods. Stage, menopausal status, comorbidity, functional status, inherited-risk indications, fertility priorities and patient preferences then shape a multidisciplinary plan.
Treatment can combine breast and axillary surgery, radiotherapy, endocrine treatment, cytotoxic chemotherapy, HER2-directed treatment, immunotherapy or other targeted therapy. The sequence and components are individual, not a menu to prescribe from a webpage. Early supportive care, rehabilitation, lymphoedema risk reduction, psychosocial support and palliative care are parts of oncology rather than evidence that disease is untreatable. This educational draft is quarantined following MedNext Clinical Team review and cannot replace examination, a pathology report or a tumour-board decision.
How Common Is It?
Breast cancer is the most frequently diagnosed cancer among women in India in the IARC Global Cancer Observatory 2022 estimate. The India fact sheet estimated 192,020 new female breast-cancer cases in 2022, representing 26.6% of estimated cancers in Indian women, and listed breast cancer as the leading cancer site in women. These are modelled population estimates, not a live national case counter. Registry coverage, case ascertainment, population projections and modelling assumptions affect the numbers, so the estimate should be cited with its year and should not be converted into an individual probability.
WHO's 2026 global fact sheet describes breast cancer as occurring in every country, with incidence increasing after puberty and later in life. It also notes that a small minority occurs in men. Population burden is not evenly distributed within India. Age structure, reproductive patterns, obesity, alcohol and tobacco exposure, awareness, screening access, urbanisation, diagnostic capacity and cancer-registry coverage differ across states and between rural and urban communities. Stage at presentation and ability to complete multimodality treatment are at least as important as incidence for outcomes.
Prevalence, incidence and mortality answer different questions. A high five-year prevalence can reflect both many diagnoses and longer survival; mortality cannot be inferred by subtracting prevalence from incidence. For a clinician, the practical message is that a persistent or suspicious breast symptom deserves timely assessment even in a younger person, while a population estimate does not justify indiscriminate imaging. For planners, local registry and service data should guide capacity. For patients, statistics inform context but do not predict a particular tumour's biology, stage, treatment response or survival.
Risk Factors
Sex and increasing age are the strongest population associations, but most people diagnosed do not have a single identifiable high-penetrance cause. Relevant history includes a pathogenic inherited variant such as BRCA1, BRCA2 or PALB2; multiple relatives with breast, ovarian, pancreatic or prostate cancer; cancer at young ages; bilateral disease; male breast cancer; and certain ancestry patterns. A careful three-generation history includes maternal and paternal branches. A family history should trigger risk assessment when appropriate, not automatic genetic testing or a promise that a negative result eliminates familial risk.
Other associated factors include previous chest irradiation at a young age, increasing postmenopausal adiposity, harmful alcohol use, tobacco exposure, some reproductive and hormonal exposures, and high mammographic density. Prior atypical ductal or lobular proliferative lesions and lobular carcinoma in situ may increase future risk. The effect size and modifiability vary, and association is not proof that an individual's behaviour caused cancer. Pregnancy, lactation and young age can make examination or imaging more complex but must not be used to postpone evaluation of a concerning mass.
Risk assessment also anticipates treatment hazards. Ask about cardiovascular disease before potentially cardiotoxic therapy, thrombosis before endocrine treatment, neuropathy, diabetes, renal or hepatic impairment, infection risk, osteoporosis, pregnancy possibility and medicines or supplements that may interact with oncology drugs. Document shoulder function and baseline arm symptoms before axillary treatment. Social risk includes distance from a cancer centre, inability to finance repeated travel, caregiving responsibilities, language barriers and fear of stigma. These factors can interrupt diagnosis or treatment and should prompt navigation support rather than blame. No diet, supplement or self-examination technique guarantees prevention.
Diagnosis
History
Define onset, change over time, laterality and relation to menstruation or lactation without assuming cyclicity is benign. Ask about a lump, focal thickening, skin dimpling, oedema, ulceration, new nipple inversion, unilateral spontaneous bloody or serous discharge, axillary swelling and persistent focal pain. Elicit fever or lactational symptoms, trauma, previous breast procedures, implants, prior cancer, radiotherapy, hormone exposure and pregnancy possibility. Constitutional symptoms, bone pain, breathlessness, neurological symptoms or jaundice can suggest advanced disease but their absence does not exclude it. Record family history on both parental sides and what the patient fears or expects.
Examination
Examine with consent, privacy and a chaperone according to local policy. Inspect both breasts for asymmetry, contour distortion, peau d'orange, erythema, ulceration and nipple change. Palpate systematically, documenting lesion site, size, consistency, mobility, skin or chest-wall fixation and multiplicity. Examine both axillae and supraclavicular regions. Consider pregnancy and lactation, infection and previous surgery when interpreting findings. A normal examination cannot overrule a clearly concerning history or abnormal image, and forceful nipple expression is not a screening test.
Investigations
Use age-, symptom- and pregnancy-appropriate diagnostic imaging through a breast service, usually targeted ultrasound with diagnostic mammography where indicated. Triple assessment requires tissue sampling of a suspicious lesion, commonly image-guided core biopsy; abnormal axillary nodes can be sampled under ultrasound guidance. Pathology should establish type and grade and test predictive biomarkers in invasive cancer. MRI is selected for defined questions such as unclear extent, difficult mammographic assessment or invasive lobular cancer when breast conservation is considered; current guidelines does not recommend routine preoperative MRI for every biopsy-proven cancer. Staging investigations are risk- and stage-directed. The team should reconcile clinical, radiological and pathological findings and resolve discordance rather than accepting the least concerning result.
Differential Diagnosis
Most breast symptoms are not malignant, but a benign label requires evidence that fits the clinical and imaging pattern. Fibroadenoma often presents as a mobile, circumscribed mass, especially in younger people, yet enlarging, atypical or discordant lesions require reassessment. Simple cysts, fibrocystic change and hormonally related mastalgia may fluctuate. Duct ectasia and intraductal papilloma can produce discharge. Fat necrosis after trauma or surgery can mimic cancer clinically and radiologically. Lipoma, hamartoma and accessory breast tissue are other possibilities, but examination alone may not reliably separate them from malignancy.
Infection includes lactational mastitis and abscess. Failure to improve as expected, a non-lactational abscess, recurrent inflammation or diffuse erythema with oedema should prompt reconsideration, including inflammatory breast cancer. Granulomatous mastitis and tuberculosis of the breast are important mimics in India; neither should be diagnosed solely from geography or a therapeutic trial. Microbiological and pathological evidence may be needed, and finding granulomatous inflammation does not automatically exclude coexisting malignancy.
Skin lesions, hidradenitis, sebaceous cysts and chest-wall masses can be mistaken for breast lesions. Paget disease should be considered when unilateral nipple eczema persists or fails appropriate treatment. Gynecomastia is usually a subareolar disc in men, whereas an eccentric hard mass, nipple change or nodes needs cancer assessment. Metastasis to the breast and lymphoma are uncommon but possible. The correct approach is concordance: if clinical suspicion, imaging and histology do not agree, the case returns for radiology-pathology review, repeat targeted sampling or excision rather than false reassurance.
Management
Management begins at a multidisciplinary meeting with verified pathology, imaging, clinical stage and the patient's goals. For operable early disease, breast-conserving surgery followed by appropriate radiotherapy can be an alternative to mastectomy when clear margins and acceptable cosmesis are feasible. Mastectomy may be indicated by disease extent, contraindication to radiotherapy, genetics, previous treatment or informed preference; it is not intrinsically the more courageous or universally safer choice. Sentinel-node assessment can reduce axillary morbidity in selected clinically node-negative disease, while proven nodal disease requires stage- and response-specific planning. Reconstruction options and timing should be discussed when mastectomy is proposed, including the option of no reconstruction.
Systemic therapy is driven by biology and risk. Endocrine treatment is relevant to hormone-receptor-positive cancer; HER2-positive disease may receive HER2-directed therapy; chemotherapy and, in defined settings, immunotherapy or other targeted agents may be considered. Neoadjuvant therapy can downstage the breast or axilla and provides response information, especially in selected HER2-positive, triple-negative or locally advanced disease. Residual disease after neoadjuvant treatment can alter postoperative therapy. Exact regimens depend on current evidence, approvals, availability, cardiac or organ function and individual risk.
Radiotherapy decisions depend on surgery, nodal status, tumour features and prior irradiation. Advanced disease is treated to prolong life, control symptoms and preserve function with subtype-directed systemic therapy, radiotherapy, procedures and integrated palliative care. Bone health, fertility, menopausal symptoms, sexual health, arm and shoulder mobility, lymphoedema, return to work and mental health require planned support. Follow-up should include treatment-toxicity review, recurrence symptoms and appropriate breast imaging, not routine whole-body scanning in every asymptomatic survivor. Completion and continuity matter; a plan that is unaffordable or unreachable needs escalation and resource-aware redesign.
Prescribing Information
Anti-cancer prescribing is a specialist, protocol-governed activity. Before any systemic treatment, verify the pathology and biomarker report, stage, treatment intent, height and weight where relevant, performance status, pregnancy status or potential, allergies, comorbidities, prior anti-cancer exposure, current medicines and organ function. Document the regimen source, cycle, route, venous-access plan, dose calculations, supportive medicines, laboratory thresholds and prescriber verification required by the treating institution. The educational categories in this guide are not sufficient to select a drug, dose or schedule.
Endocrine medicines differ by menopausal status and ovarian function and carry distinct risks, including thromboembolism, endometrial effects, menopausal symptoms and bone loss. HER2-directed agents require confirmation of HER2 status and may require cardiac assessment and surveillance. Cytotoxic regimens can cause myelosuppression, infection, nausea, mucositis, alopecia, neuropathy, cardiotoxicity or organ-specific injury. Immunotherapy can cause inflammatory toxicities affecting almost any organ. Targeted agents have mutation-, receptor- and product-specific indications and interactions. These risks must be explained using the actual regimen and current product information.
Fever or clinical deterioration during systemic treatment requires immediate use of the local neutropenic-sepsis pathway; patients should have a 24-hour contact route. New dyspnoea, chest pain, severe diarrhoea, jaundice, confusion, uncontrolled vomiting, bleeding or infusion reaction warrants urgent assessment. Review fertility preservation before gonadotoxic treatment when time and clinical circumstances permit, and address contraception without assuming infertility. Do not combine anticancer medicines with unverified supplements or traditional products without interaction review. Antiemetics, analgesia, growth factors, bone-modifying therapy and antimicrobial prophylaxis are prescribed for defined indications, not added automatically. Safe prescribing includes pharmacy verification, administration checks, toxicity grading and a documented stop, hold or escalation plan.
When to Refer
Any new clinically suspicious breast or axillary finding should enter a diagnostic breast pathway promptly. Referral information should describe the exact symptom and duration, examination findings in both breasts and nodal basins, pregnancy or lactation, previous imaging or procedures, personal cancer history, relevant family history and contact barriers. A hard irregular or fixed mass, skin tethering, peau d'orange, new unilateral nipple inversion, spontaneous blood-stained discharge, persistent unilateral nipple change, suspicious male breast mass or unexplained axillary node should not be managed by prolonged empirical treatment. Normal recent screening does not cancel a new symptom.
Expedite assessment for rapidly progressive inflammatory change, ulceration, fungation, neurological symptoms, pathological fracture concern, spinal pain with neurological deficit, significant breathlessness or other possible metastatic complication. Suspected sepsis, major bleeding, superior vena cava obstruction, spinal cord compression or hypercalcaemic deterioration needs emergency evaluation rather than an outpatient appointment. A lactating person with probable infection still needs reassessment if response is incomplete or a focal mass persists.
After diagnosis, refer into a multidisciplinary service with breast surgery, radiology, pathology, medical and radiation oncology access, and supportive and palliative care. Genetics referral is based on age, tumour features and family history according to an applicable pathway. Fertility, pregnancy, complex reconstruction, severe comorbidity and treatment-related cardiac, neurological or endocrine toxicity may require additional specialists. In India, routes may include district hospitals, medical colleges, state cancer institutes, National Cancer Grid centres, charitable hospitals and private services. Confirm the actual receiving service and anticipated test availability; a referral letter without navigation, records transfer or a follow-up plan can leave the patient functionally un-referred.
Red Flags
Breast cancer itself is not usually a minute-to-minute emergency, but certain presentations require rapid escalation. Diffuse erythema, oedema or peau d'orange involving a substantial area, rapid breast enlargement and palpable nodes can indicate inflammatory cancer and should not receive repeated antibiotic courses without reassessment. An ulcerating or bleeding mass, uncontrolled pain, malodour with systemic illness or severe anaemia needs urgent oncology and wound-care input. Fever, hypotension, confusion or rigors in a person receiving systemic therapy may represent neutropenic sepsis even when the temperature is not dramatically high.
Possible metastatic emergencies include new severe or progressive back pain with weakness, sensory change, gait disturbance or bladder or bowel dysfunction; new focal neurological deficit, seizure or persistent vomiting; acute breathlessness or hypoxia; and marked dehydration, confusion or arrhythmia compatible with metabolic disturbance. These require emergency assessment and should not wait for a routine oncology visit. Unilateral arm swelling after nodal treatment may be lymphoedema, but acute painful swelling, erythema, chest pain or dyspnoea also raises infection or venous thrombosis.
Treatment red flags depend on the agent. New heart-failure symptoms during potentially cardiotoxic therapy, severe diarrhoea or hepatitis during immunotherapy, major bleeding, anaphylaxis, vesicant extravasation and inability to maintain oral intake need protocol-led care. Pregnancy discovered during treatment requires urgent multidisciplinary review, not abrupt unsupervised cessation. Psychosocial red flags include suicidal thoughts, coercion, inability to obtain food or transport, and abandonment of curative treatment because of avoidable system barriers. A safety plan should give the patient written warning symptoms and a contact that functions outside clinic hours.
Indian Clinical Context
The IARC 2022 India estimate places breast cancer first among cancers in women, with 192,020 estimated new cases. This burden sits within substantial variation in registry coverage, stage at diagnosis and access to high-quality pathology, imaging, radiotherapy, systemic medicines and reconstructive care. The number should support urgency and service planning, not imply that every breast symptom is malignant. WHO's early-diagnosis framework is especially relevant: awareness must connect to timely clinical evaluation, diagnosis and treatment. Awareness activity without biopsy capacity or treatment navigation can simply move delay to another part of the pathway.
Indian care is delivered through heterogeneous public, teaching, charitable and private systems. Some centres offer integrated triple assessment and same-day coordination; elsewhere imaging, pathology and oncology occur in different institutions. Preserve original slides or blocks, imaging in a transferable format, receptor reports and treatment summaries. Pathology quality matters because a false or incomplete biomarker result can redirect months of therapy. When cost or travel threatens completion, discuss government benefit pathways, social-work support, generic or biosimilar policy and referral to a resource-appropriate cancer centre without promising eligibility or availability.
Population screening policy is jurisdiction-specific. Do not import an public health guidance invitation age or a foreign low-dose protocol into India and present it as national policy. Symptomatic diagnosis is distinct from screening an asymptomatic population. Clinical breast examination programmes, mammography access and high-risk surveillance vary; apply current national or state guidance and local capacity. Similarly, current guidelines recommendations offer transparent evidence-informed principles but reflect UK commissioning, licensing and service structures. Indian tumour boards must use current local protocols, regulatory approvals, pathology capability, radiotherapy access and patient priorities. Communication in a preferred language, avoidance of stigma, inclusion of chosen family and explicit plans for travel and toxicity care are clinical quality measures.
NMC Competency Mapping
The NMC CBME 2024 curriculum provides an undergraduate framework rather than specialist authorization. SU25.1 addresses applied anatomy and appropriate investigation of breast disease. SU25.3 covers the etiopathogenesis, clinical features, investigations and principles of treatment of benign and malignant breast tumours. PA6.2 links molecular carcinogenesis to common cancers including breast cancer, while PA6.5 addresses laboratory cancer diagnosis, molecular profiles and tumour markers. These competencies support a coherent learner pathway from a breast complaint to tissue diagnosis and multidisciplinary principles.
At undergraduate level, the learner should take a respectful breast history, obtain consent, perform a supervised systematic examination and describe a lesion precisely. They should explain why clinical assessment, imaging and pathology must be concordant; distinguish diagnostic evaluation from population screening; recognise inflammatory change and metastatic emergencies; and interpret ER, PR and HER2 as predictive and prognostic information without independently prescribing. They should understand broad TNM logic, nodal drainage, sentinel-node principles and the difference between in-situ, invasive, locally advanced and metastatic disease.
Competence also includes communication. A student should avoid announcing cancer before pathology, explain why biopsy is needed, preserve uncertainty honestly and make a usable referral. Counselling should acknowledge body image, sexuality, fertility, reconstruction, financial toxicity and fear. Examination, biopsy, cancer staging and systemic treatment all require supervision and local protocols. Reading this guide does not certify breast examination, image interpretation, pathology sign-out, surgery or oncology prescribing. Assessment should test clinical reasoning and safety, not memorisation of one regimen that may change with stage, biomarker evidence or availability.
Key Exam Pearls for NEET PG
A painless hard irregular breast lump, skin tethering, peau d'orange, new nipple retraction and hard axillary nodes are classic warning features, but pain does not exclude malignancy. The upper outer quadrant is a common site and axillary drainage dominates regional spread. Inflammatory breast cancer presents with rapid erythema and oedema and may lack a discrete mass. Paget disease causes persistent eczematous nipple change and is associated with underlying ductal malignancy. Male breast cancer is uncommon but a suspicious eccentric mass requires the same diagnostic seriousness.
Triple assessment means clinical assessment, imaging and tissue diagnosis. Ultrasound is valuable for targeted lesion and axillary evaluation; diagnostic mammography assesses both breasts and detects features such as suspicious calcification or architectural distortion. Core biopsy generally provides architecture and tissue for receptor testing. Fine-needle cytology alone cannot always distinguish in-situ from invasive disease. Discordant benign pathology does not end the work-up. ER and PR predict endocrine responsiveness; HER2 status directs HER2-targeted therapy. Triple-negative refers to absence of ER, PR and HER2 expression, not to a negative triple assessment.
Breast conservation usually requires complete excision with appropriate radiotherapy and is oncologically distinct from simply removing a lump. Sentinel-node biopsy stages the clinically negative axilla with less morbidity than routine full dissection in selected disease. Neoadjuvant therapy is treatment before definitive surgery; adjuvant therapy follows surgery. Tamoxifen is a selective oestrogen-receptor modulator with thromboembolic and endometrial risks; aromatase inhibition is associated with bone loss; anthracyclines and HER2-directed therapy raise cardiac-monitoring questions. Stage and biology, not tumour size alone, determine systemic treatment. Spinal cord compression, neutropenic sepsis, severe hypercalcaemia and acute respiratory compromise are oncology emergencies.
Frequently Asked Questions
Can a painful breast lump still be breast cancer?
Yes. Many malignant lumps are painless, but pain does not rule cancer out and benign conditions can also be painless. A new persistent or clinically suspicious lump needs assessment based on examination, appropriate imaging and, when indicated, tissue sampling rather than reassurance from pain alone.
Does a normal recent mammogram rule out cancer when a new lump is present?
No. Screening and diagnostic assessment answer different questions, and some cancers are occult or difficult to characterise on mammography. A new focal symptom requires clinical review and targeted imaging, with biopsy when findings are suspicious or clinical, radiological and pathological results do not agree.
Is mastectomy always safer than breast-conserving treatment?
No. For appropriately selected early cancers, breast-conserving surgery with indicated radiotherapy can provide effective local treatment. Choice depends on disease extent, margins, genetics, prior radiotherapy, expected cosmetic result, access to radiotherapy and informed preference. The multidisciplinary team should explain recurrence and complication trade-offs.
Why must ER, PR and HER2 be tested before choosing treatment?
These biomarkers define important tumour biology and predict benefit from endocrine or HER2-directed treatment. They also help frame chemotherapy and neoadjuvant decisions. Testing must use validated pathology methods, and an equivocal or discordant result may require repeat or confirmatory evaluation before therapy is selected.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic